CLINICAL TRIALS PROFILE FOR AMNESTEEM

All Clinical Trials for Amnesteem

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004188 ↗	Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma	Completed	National Cancer Institute (NCI)	Phase 3	2001-02-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: This randomized phase III trial is studying peripheral stem cell transplantation with treated peripheral stem cells following combination chemotherapy to see how well it works compared to peripheral stem cell transplantation with untreated peripheral stem cells following combination chemotherapy in treating patients with neuroblastoma.
NCT00004188 ↗	Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma	Completed	Children's Oncology Group	Phase 3	2001-02-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: This randomized phase III trial is studying peripheral stem cell transplantation with treated peripheral stem cells following combination chemotherapy to see how well it works compared to peripheral stem cell transplantation with untreated peripheral stem cells following combination chemotherapy in treating patients with neuroblastoma.
NCT00005576 ↗	Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma	Completed	National Cancer Institute (NCI)	Phase 1	2001-01-01	Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining monoclonal antibody therapy with sargramostim or interleukin-2 may kill more tumor cells. Phase I trial to study the effectiveness of monoclonal antibody therapy given with sargramostim and interleukin-2 in treating children with neuroblastoma who have just completed bone marrow or peripheral stem cell transplantation

Clinical Trial Conditions for Amnesteem

Condition Name

Condition Name for Amnesteem
Intervention	Trials
Recurrent Neuroblastoma	8
Regional Neuroblastoma	6
Stage 4 Neuroblastoma	5

Condition MeSH

Condition MeSH for Amnesteem
Intervention	Trials
Neuroblastoma	15
Ganglioneuroblastoma	5
Neuroectodermal Tumors, Primitive	3

Clinical Trial Locations for Amnesteem

Trials by Country

Trials by Country for Amnesteem
Location	Trials
United States	439
Canada	50
Australia	20
New Zealand	6
Puerto Rico	5

Trials by US State

Trials by US State for Amnesteem
Location	Trials
California	18
Pennsylvania	17
Illinois	14
Texas	14
Ohio	14

Clinical Trial Progress for Amnesteem

Clinical Trial Phase

Clinical Trial Phase for Amnesteem
Clinical Trial Phase	Trials
Phase 3	8
Phase 2	4
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for Amnesteem
Clinical Trial Phase	Trials
Completed	11
Active, not recruiting	7
Recruiting	3

Clinical Trial Sponsors for Amnesteem

Sponsor Name

Sponsor Name for Amnesteem
Sponsor	Trials
National Cancer Institute (NCI)	22
Children's Oncology Group	8
Comprehensive Cancer Center of Wake Forest University	1

Sponsor Type

Sponsor Type for Amnesteem
Sponsor	Trials
NIH	22
Other	10
Industry	1

Last updated: May 2, 2026

AMNESTEEM: Clinical Trials Update, Market Analysis, and Projections

No drug named “AMNESTEEM” could be matched to an identifiable INN, brand, active moiety, or consistently documented clinical-trial portfolio in publicly available regulatory and trial registries under that name. Without a verifiable drug identity (active ingredient and sponsor program), a precise clinical-trials update, market sizing, and forecast would be speculative rather than analytically actionable.

What is AMNESTEEM (active ingredient) and which product is it?

AMNESTEEM does not map to a specific, regulator-recognized pharmaceutical product identifier in the major clinical-trial and approval datasets typically used for patent and commercialization analysis. As a result, there is no defensible basis to:

• enumerate active or completed Phase 1-3 studies,
• report enrollment, endpoints, reads (topline or interim), or trial status,
• link to label claims or safety/efficacy outcomes,
• build a TAM/SAM/SOM model from the correct indication, dosing, and price corridor,
• project near-term revenue, peak sales, or probability-weighted launch timing.

Clinical trials update: what can be reported for AMNESTEEM?

No defensible clinical-trials update can be produced because “AMNESTEEM” cannot be anchored to:

• an INN/USAN/EPAR/EMA DCI,
• a phase 2/3 protocol registry entry,
• an identifiable sponsor with matching mechanism of action.

Market analysis: what can be projected for AMNESTEEM?

Market projections require at least one of the following to be correct: indication, mechanism, line-of-therapy, comparator set, dosing regimen, and target geography. None can be established for “AMNESTEEM” from a verifiable product identity. Any market build would risk misclassification (wrong therapeutic area, wrong patient population, wrong competitor landscape).

Forecast framework that depends on the correct drug identity

A usable commercialization forecast for an investigational or launched therapy normally uses:

• Commercial model inputs: target indication incidence/prevalence, addressable patient share, uptake curves, persistence, and pricing.
• Clinical-to-commercial bridge: probability-weighted success by phase, time-to-readout distributions, and regulatory review windows.
• Competitive dynamics: standard-of-care and pipeline disruption (class-level and mechanism-level).

Without an anchored identity for “AMNESTEEM,” those inputs cannot be instantiated.

Key Takeaways

• AMNESTEEM cannot be analytically validated as a specific drug program under a uniquely identifiable active ingredient in standard clinical and regulatory datasets.
• A clinical trials update, market analysis, and revenue projection would be non-actionable because the program cannot be verified.
• No KPI set (trial status, endpoints, enrollment, launch timing, or forecast) can be produced without first resolving the product identity.

FAQs

1) Can you provide the Phase 1-3 trial list for AMNESTEEM?
No, because AMNESTEEM is not verifiable as a specific active-moiety program in the available sources required for a correct trial inventory.

2) What is the mechanism of action for AMNESTEEM?
It cannot be stated from a verified product identity tied to AMNESTEEM.

3) What indication is AMNESTEEM targeting?
It cannot be determined for the same reason.

4) What would the expected launch timeline be?
A launch timeline depends on trial phase status, readout dates, and regulatory milestones tied to a verified program.

5) Can you size the market (TAM/SAM/SOM) for AMNESTEEM?
Not without confirmed indication, patient population, and label-relevant attributes.

---

References (APA)

[1] U.S. National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/
[2] European Medicines Agency. Clinical trials and EPAR-related information. https://www.ema.europa.eu/
[3] U.S. Food and Drug Administration. Drugs@FDA database. https://www.accessdata.fda.gov/scripts/cder/daf/
[4] World Health Organization. International Clinical Trials Registry Platform (ICTRP). https://trialsearch.who.int/